Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure

Xie, Ruiqin; Cui, Wei; Fan, Li; Yang, Caiqin; Pei, Weina; Lu, Jingchao

doi:10.1016/j.ijcard.2008.11.030

Cited by 32 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that the decrease of QTc was correlated with the increase of LVEF and the therapy of shortening QTc improved cardiac function,[25] which is consistent with our findings. The current study revealed that NRG rats QTc was shorter than HF rats with the improvement of cardiac function.…”

Section: Discussionsupporting

confidence: 92%

Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure

Wang

Zhuo²,

Ni³

et al. 2012

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

ObjectiveWe performed experiments using Neuregulin-1β (NRG-1β) treatment to determine a mechanism for the protective role derived from its beneficial effects by remodeling gap junctions (GJs) during heart failure (HF).MethodsRat models of HF were established by aortocaval fistula. Forty-eight rats were divided randomly into the HF (HF, n = 16), NRG-1β treatment (NRG, n = 16), and sham operation (S, n = 16) group. The rats in the NRG group were administered NRG-1β (10 µg/kg per day) for 7 days via the tail vein, whereas the other groups were injected with the same doses of saline. Twelve weeks after operation, Connexin 43 (Cx43) expression in single myocytes obtained from the left ventricle was determined by immunocytochemistry. Total protein was extracted from frozen left ventricular tissues for immunoblotting assay, and the ultrastructure of myocytes was observed by transmission electron microscopy.ResultsCompared with the HF group, the cardiac function of rats in the NRG group was markedly improved, irregular distribution and deceased Cx43 expression were relieved. The ultrastructure of myocytes was seriously damaged in HF rats, and NRG-1β reduced these pathological damages.ConclusionsShort-term NRG-1β treatment can rescue pump failure in experimental models of volume overload-induced HF, which is related to the recovery of GJs structure and the improvement of Cx43 expression.

show abstract

Section: Discussionsupporting

confidence: 92%

Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure

Wang

Zhuo²,

Ni³

et al. 2012

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

show abstract

“…Furthermore, similar to our findings on systolic performance, clinical trials show that atorvastatin improves left ventricular systolic function and symptoms of heart failure in patients with nonischemic cardiomyopathy [Sola et al 2006] and chronic heart failure [Yamada et al 2007;Xie et al 2010]. However, not all statins are equally effective in improving systolic function.…”

Section: Discussionsupporting

confidence: 85%

Atorvastatin improves systolic function, but does not prevent the development of dilated cardiomyopathy in streptozotocin-induced diabetic rats

Quidgley

Cruz

Crespo

2014

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Whereas atorvastatin does not reverse ventricular dilatation, it does have a positive hemodynamic effect on the CV system of diabetic rats. This hemodynamic benefit is independent of cholesterol levels, and is observed concomitantly with reduced oxidative stress, vascular remodeling, and improved endothelial function. Together, these results suggest that atorvastatin decreases the workload on the heart and improves systolic performance in type 1 diabetic rats by reducing oxidative stress, vascular tone, and systemic vascular resistance.

show abstract

“…Statin therapy has also been found to be associated with improved QT dynamics in heart failure patients 18. In our study there was no significant difference between patients on statin therapy and those without statins, according to QTc and QTcd parameters at baseline ( p > 0.05 for all).…”

Section: Discussioncontrasting

confidence: 53%

Nebivolol therapy improves QTc and QTcd parameters in heart failure patients

S²,

Çağırcı

et al. 2012

Cardiovascular Journal of Africa

View full text Add to dashboard Cite

AimIt has previously been shown that β-blocker therapy reduces QT dynamics in heart failure patients. The aim of this study was to demonstrate this improvement with the third-generation β-blocker, nebivolol.MethodsA total of 72 heart failure patients with systolic dysfunction were included in the study. Corrected QT (QTc) and QT dispersion (QTcd) were measured manually by two independent observers at baseline and after nebivolol use (5 mg/day) in the first and third months of follow up.ResultsBoth QTc and QTcd were found to be significantly reduced in the first (455.3 ± 26.7 vs 441.2 ± 25.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 58.2 ± 5.6 ms, p = 0.001 for QTcd) and third months (455.3 ± 26.7 vs 436.0 ± 28.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 56.0 ± 6.2 ms, p < 0.001 for QTcd) compared with baseline values.ConclusionNebivolol was associated with improved QT dynamics in heart failure patients with systolic dysfunction.

show abstract

Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure

Cited by 32 publications

References 8 publications

Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure

Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure

Atorvastatin improves systolic function, but does not prevent the development of dilated cardiomyopathy in streptozotocin-induced diabetic rats

Nebivolol therapy improves QTc and QTcd parameters in heart failure patients

Contact Info

Product

Resources

About